Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

75.15
+1.091.46%
Post-market: 74.67-0.4800-0.64%19:39 EST
Volume:1.60M
Turnover:119.10M
Market Cap:14.48B
PE:-17.96
High:75.24
Open:73.83
Low:72.65
Close:74.07
52wk High:75.24
52wk Low:25.34
Shares:192.71M
Float Shares:151.20M
Volume Ratio:0.93
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1844
EPS(LYR):-2.8793
ROE:-1789.67%
ROA:-43.47%
PB:-7.49
PE(LYR):-26.10

Loading ...

TD Cowen Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

TIPRANKS
·
Oct 30

Director Frank McCormick Reports Sale of BridgeBio Pharma Inc. Common Shares

Reuters
·
Oct 30

Stock Track | BridgeBio Pharma Plunges 6% After Hours on Q3 Earnings Miss Despite Revenue Beat

Stock Track
·
Oct 30

BRIEF-BridgeBio Pharma Q3 Net Income USD -184.937 Million

Reuters
·
Oct 30

BridgeBio Pharma Reports $120.7 Million Q3 Revenue and $182.7 Million Net Loss

Reuters
·
Oct 30

BridgeBio Pharma Q3 EPS USD -0.95

THOMSON REUTERS
·
Oct 30

BUZZ-U.S. STOCKS ON THE MOVE- Verisk, Fiserv, Boeing

Reuters
·
Oct 30

BridgeBio price target raised to $90 from $80 at H.C. Wainwright

TIPRANKS
·
Oct 29

BridgeBio Pharma Inc : Piper Sandler Raises Target Price to $93 From $80

THOMSON REUTERS
·
Oct 29

BridgeBio Pharma Inc : Jefferies Raises Target Price to $85 From $75

THOMSON REUTERS
·
Oct 29

BridgeBio Reports Positive Phase 3 Topline Results For Encaleret In Patients With Autosomal Dominant Hypocalcemia Type 1

Reuters
·
Oct 29

BridgeBio's drug for genetic condition meets main goals in late-stage study

Reuters
·
Oct 29

BridgeBio Pharma Inc: Encaleret Was Well-Tolerated With No Discontinuations Related to Study Drug

THOMSON REUTERS
·
Oct 29

BridgeBio Pharma Inc: Plans to Initiate Registrational Studies of Encaleret in Chronic Hypoparathyroidism and Pediatric Adh1 in 2026

THOMSON REUTERS
·
Oct 29

BridgeBio Pharma Inc - Nda Submission Planned in First Half of 2026

THOMSON REUTERS
·
Oct 29

BridgeBio Pharma Inc - 91% of Encaleret Participants Achieved Intact Pth Above Reference Range

THOMSON REUTERS
·
Oct 29

Stock Track | BridgeBio Pharma Surges 5.16% in Pre-market on Anticipation of Phase 3 Trial Results

Stock Track
·
Oct 29

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Oct 29

Stock Track | BridgeBio Pharma Soars 5.12% Ahead of Crucial Phase 3 Trial Results Announcement

Stock Track
·
Oct 29

Stock Track | BridgeBio Pharma Soars 5.12% Ahead of Crucial Phase 3 Trial Results Announcement

Stock Track
·
Oct 29